Previous Close | 19.49 |
Open | 19.45 |
Bid | 18.63 x 800 |
Ask | 18.77 x 900 |
Day's Range | 18.35 - 19.45 |
52 Week Range | 9.85 - 32.45 |
Volume | |
Avg. Volume | 482,442 |
Market Cap | 640.483M |
Beta (5Y Monthly) | 0.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.60 |
Earnings Date | May 09, 2023 - May 15, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 42.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for RAPT
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Company maintains strong cash position of $249.1 millionSOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2022. “2022 was an important year
Rapt Therapeutics (RAPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.